Sign In
Buy MRNA
$59.81
+0.640 (+1.08%)
At Close: Aug 10, 2026
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
07:25pm, Thursday, 12'th Jun 2025
Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the
Is it Time to Dump Your Shares of Moderna?
04:25am, Thursday, 12'th Jun 2025
After soaring to success in the early days of the COVID-19 pandemic, Moderna (MRNA 0.25%) experienced a reversal of fortune. The coronavirus vaccine maker has seen revenue plummet as demand for this f
Moderna, Inc. (MRNA) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
08:38pm, Wednesday, 11'th Jun 2025
Moderna, Inc. (NASDAQ:MRNA ) Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 8:40 AM ET Company Participants Stéphane Bancel - CEO & Director Conference Call Participants Salveen
Moderna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025
07:00am, Wednesday, 11'th Jun 2025
CAMBRIDGE, MA / ACCESS Newswire / June 11, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor event: Barclays Speaking the Science Call Series, on
RFK Jr.'s firing of CDC vaccine advisors 'circumvents science' and could threaten public health, experts say
11:50am, Tuesday, 10'th Jun 2025
Health and Human Services Secretary Robert F. Kennedy Jr. has gutted a key government panel of vaccine advisors, a stunning move that some public health experts say undermines science, disrupts a trus
Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up
09:30am, Tuesday, 10'th Jun 2025
Shares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S. Health Secretary Robert F. Kennedy Jr. fired all members of an expert vaccin
Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors.
08:18am, Tuesday, 10'th Jun 2025
Investors will be waiting for news on how the makeup of a reconstituted ACIP will look like.
What Sparked Moderna Stock Crash?
07:40am, Tuesday, 10'th Jun 2025
Moderna's stock (NASDAQ: MRNA) has fallen over 80% in the last year, primarily due to issues with its vaccine sales. Last year, the company revealed reduced sales forecasts in Europe after the Europea
Vaccine Stocks Moderna, Pfizer Hit After A Surprise Blow From RFK Jr.
06:07pm, Monday, 09'th Jun 2025
Vaccines stocks slipped late Monday after HHS fired all members of a CDC committee in charge of making vaccine suggestions.
Moderna, Inc. (MRNA) Presents at Jefferies Global Healthcare Conference Transcript
01:39pm, Thursday, 05'th Jun 2025
Moderna, Inc. (NASDAQ:MRNA ) Jefferies Global Healthcare Conference Call June 5, 2025 10:30 AM ET Company Participants Stephen Hoge - President Conference Call Participants Michael Jonathan Yee - Jeff
Down 80%, Should You Buy the Dip on Moderna?
04:15am, Wednesday, 04'th Jun 2025
A few years ago, Moderna (MRNA 2.77%) stock represented the ticket to an investing win. The company brought its coronavirus vaccine from drawing board to commercialization in less than a year and saw
Moderna agrees to true placebo-controlled trial of new COVID vaccine, Kennedy says
05:36pm, Tuesday, 03'rd Jun 2025
U.S. Health and Human Services Secretary Robert F. Kennedy Jr. said on Tuesday that Moderna has agreed to a true placebo-controlled trial of its new COVID-19 vaccine.
Moderna Secures FDA Nod for Next-Gen COVID-19 Vaccine mNexspike
01:21pm, Tuesday, 03'rd Jun 2025
MRNA wins FDA approval for mNexspike, a fridge-stable COVID shot, but with a narrower use label than it sought.
The biotech's mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to vaccine rules.
Moderna: Vaccine Approval (Finally!) Provides A Reason To Be Cheerful
01:25pm, Monday, 02'nd Jun 2025
Moderna's new COVID vaccine approval targets a broader high-risk population, but the market remains skeptical due to limited revenue prospects and ongoing losses. Management is pivoting to cost-cuttin
